Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement | Zendy

David Goldsmith | Zendy; Adrian Covic | Zendy; Marc G. Vervloet | Zendy; Mario Cozzolino | Zendy; Ionuţ Nistor | Zendy; Chronic Kidney Disease-Mineral Bone Disease | Zendy; Vincent Brandenburg | Zendy; Jordi Bover | Zendy; P. Evenepoel | Zendy; Ziad A. Massy | Zendy; Sandro Mazzaferro | Zendy; Pablo Ureña-Torres | Zendy; Daniel Abramowicz | Zendy; Davide Bolignano | Zendy; G. Cannata Andia | Zendy; P. Cochat | Zendy; Lucia DelVecchio | Zendy; Christiane Drechsler | Zendy; KaiUwe Eckardt | Zendy; D. Fouque | Zendy; Jonathan Fox | Zendy; Maria Haller | Zendy; Olof Heimbürger | Zendy; Kitty J. Jager | Zendy; Elizabeth Lindley | Zendy; Anna Martí i Monros | Zendy; Evi Nagler | Zendy; Rainer Oberbauer | Zendy; G. Spasovski | Zendy; James Tattersall | Zendy; Wim Van Biesen | Zendy; Sachin Veer | Zendy; Raymond Vanholder | Zendy; C. Wanner | Zendy; Wheeler Dc | Zendy; William Whithers | Zendy; A. Wiecek | Zendy; Carmine Zoccali | Zendy

Open Access

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

Author(s) -

David Goldsmith,

Adrian Covic,

Marc G. Vervloet,

Mario Cozzolino,

Ionuţ Nistor,

Chronic Kidney Disease-Mineral Bone Disease,

Vincent Brandenburg,

Jordi Bover,

P. Evenepoel,

Ziad A. Massy,

Sandro Mazzaferro,

Pablo Ureña-Torres,

Daniel Abramowicz,

Davide Bolignano,

G. Cannata Andia,

P. Cochat,

Lucia DelVecchio,

Christiane Drechsler,

KaiUwe Eckardt,

D. Fouque,

Jonathan Fox,

Maria Haller,

Olof Heimbürger,

Kitty J. Jager,

Elizabeth Lindley,

Anna Martí i Monros,

Evi Nagler,

Rainer Oberbauer,

G. Spasovski,

James Tattersall,

Wim Van Biesen,

Sachin Veer,

Raymond Vanholder,

C. Wanner,

Wheeler Dc,

William Whithers,

A. Wiecek,

Carmine Zoccali

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv050

Subject(s) - medicine , calcimimetic , position statement , cinacalcet , workgroup , secondary hyperparathyroidism , guideline , hyperparathyroidism , position (finance) , urology , intensive care medicine , family medicine , parathyroid hormone , pathology , computer network , finance , computer science , economics , calcium

This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research